Pharmaceutical Executive
Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Catarina Costa Pinheiro
Advertisement
Articles by Catarina Costa Pinheiro
Advertisement
Latest Updated Articles
CMED: The ‘Curupira’ of Brazil’s Pharma MarketFebruary 21st 2017
Advertisement
Advertisement
Trending on PharmExec
1
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Lonza to Acquire Five U.S. CDMO Sites From Merck KGaA
4
Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie
5